According to the terms of the agreement, Sanofi will acquire London-based Vicebio’s entire share capital for an upfront ...

Respiratory syncytial virus (RSV) infections in older adults lead to significantly more severe health outcomes and long-term cardiovascular complications compared to other common causes of ...

Respiratory syncytial virus (RSV) is a well-known cause of infections in children, but it's understudied in older individuals ...

Changes at the federal government level have raised concerns about vaccine access here on Vashon for three important respiratory disease vaccines — COVID, influenza (flu), and Respiratory Syncytial ...

Sanofi has signed an agreement to acquire Vicebio’s share capital for $1.15bn upfront, to expand its vaccine development capabilities.

Respiratory syncytial virus (RSV) poses a significant, often overlooked, risk for serious cardiovascular complications in ...

Respiratory syncytial virus (RSV) is a well-known cause of infections in children, but it's understudied in older individuals. In a retrospective study published in the Journal of the American ...